## Anaplastic Thyroid Carcinoma: Aggressive Biology & Poor Prognosis **Key Point:** Anaplastic thyroid carcinoma is the most aggressive thyroid malignancy, characterized by rapid growth, early distant metastases, and uniformly poor prognosis. It does NOT respond to radioactive iodine because it loses the ability to concentrate iodine. ### Epidemiology & Origin | Feature | Details | |---------|----------| | Frequency | 1–2% of thyroid cancers | | Age of onset | Typically >60 years | | Origin | 20–30% arise from pre-existing differentiated cancer (PTC or FTC) | | Dedifferentiation | Often represents transformation of indolent tumors to aggressive phenotype | **High-Yield:** ATC can arise de novo or from dedifferentiation of papillary or follicular carcinoma. The transition is marked by loss of thyroglobulin production and iodine-concentrating capacity. ### Molecular Genetics 1. **Most Common Alterations** - **TP53 mutations**: Present in >70% of cases (tumor suppressor loss) - **BRAF V600E**: Found in 25–40% of cases - **RAS mutations**: Present in 20–30% of cases - **PTEN loss**: Frequent (loss of phosphatase and tensin homolog) - **PI3K/AKT pathway activation**: Common **Mnemonic: "TP53 BRAF RAS PTEN"** — the four major drivers of ATC transformation. ### Loss of Differentiation = Loss of Iodine Uptake 2. **Why ATC Does NOT Respond to Radioactive Iodine** - Anaplastic cells lose expression of the sodium-iodide symporter (NIS) - No thyroglobulin production - Cannot concentrate radioactive iodine - RAI scan shows "cold" nodule (no uptake) - RAI therapy is ineffective **Clinical Pearl:** A thyroid mass that is "cold" on RAI scan (no uptake) is more likely to be anaplastic or poorly differentiated. In contrast, papillary and follicular carcinomas retain iodine-concentrating capacity and show uptake on RAI scan. ### Clinical Behavior & Prognosis 3. **Aggressive Features** - Rapid growth (weeks to months) - Early invasion of surrounding structures (trachea, esophagus, laryngeal nerve) - Distant metastases at presentation in 50% of cases - Lung (80%), bone (15%), brain (10%) 4. **Dismal Prognosis** - Median survival: 3–6 months from diagnosis - 1-year survival: <20% even with multimodal therapy - 5-year survival: <5% ### Treatment Approach - **Surgery**: Attempted if resectable for airway protection; rarely curative - **External beam radiation**: Palliative - **Chemotherapy**: Doxorubicin-based regimens; modest benefit - **Targeted therapy**: BRAF inhibitors (dabrafenib) + MEK inhibitors (trametinib) for BRAF-mutant ATC; emerging role - **Immunotherapy**: Checkpoint inhibitors (pembrolizumab) under investigation - **Radioactive iodine**: NOT effective (no iodine uptake) **Warning:** ~~ATC responds well to RAI~~ — FALSE. This is a critical trap. ATC loses differentiation and therefore loses the ability to concentrate iodine. RAI is contraindicated in ATC. ### Why Option 3 is Incorrect Option 3 claims ATC demonstrates "excellent response to radioactive iodine ablation due to retained iodine-concentrating capacity." This is fundamentally wrong: - ATC cells are undifferentiated and lose NIS expression - They do NOT concentrate iodine - RAI is ineffective and not used in ATC - This describes papillary or follicular carcinoma, not anaplastic carcinoma [cite:Robbins 10e Ch 24]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.